StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) stock

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$103.87−0.61 (-0.58%)

Close on Nov 19, 2026Market cap $179.74BP/E 33.4Yield 2.31%

Abbott Laboratories free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Abbott Laboratories's free cash flow for the twelve months ending Jun 30, 2026 was $7.82B, up 15.5% year over year. For fiscal 2025 it was $7.40B, up 16.4% from the year before. Over ten years it grew 14.8% a year on average. The highest annual figure on record is $8.65B in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.40B+16.4%
FY2024Dec 31, 2024$6.35B+25.5%
FY2023Dec 31, 2023$5.06B-35.2%
FY2022Dec 31, 2022$7.80B-9.8%
FY2021Dec 31, 2021$8.65B+51.1%
FY2020Dec 31, 2020$5.72B+27.3%
FY2019Dec 31, 2019$4.50B-8.3%
FY2018Dec 31, 2018$4.91B+10.6%
FY2017Dec 31, 2017$4.44B+113.0%
FY2016Dec 31, 2016$2.08B+12.2%
FY2015Dec 31, 2015$1.86B-28.6%
FY2014Dec 31, 2014$2.60B+19.2%
FY2013Dec 31, 2013$2.18B-71.0%
FY2012Dec 31, 2012$7.52B+0.5%
FY2011Dec 31, 2011$7.48B-3.1%
FY2010Dec 31, 2010$7.72B+24.8%
FY2009Dec 31, 2009$6.19B+8.4%
FY2008Dec 31, 2008$5.71B+61.8%
FY2007Dec 31, 2007$3.53B–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.99B+28.9%
Q1 FY2026Mar 31, 2026$916.00M-1.8%
Q4 FY2025Dec 31, 2025$2.63B+22.3%
Q3 FY2025Sep 30, 2025$2.29B+6.6%
Q2 FY2025Jun 30, 2025$1.55B+8.3%
Q1 FY2025Mar 31, 2025$933.00M+48.8%
Q4 FY2024Dec 31, 2024$2.15B-5.9%
Q3 FY2024Sep 30, 2024$2.15B+63.2%
Q2 FY2024Jun 30, 2024$1.43B+105.0%
Q1 FY2024Mar 31, 2024$627.00M-17.8%
Q4 FY2023Dec 31, 2023$2.28B+33.0%
Q3 FY2023Sep 30, 2023$1.32B-43.1%
Q2 FY2023Jun 30, 2023$696.00M-65.7%
Q1 FY2023Mar 31, 2023$763.00M-56.3%
Q4 FY2022Dec 31, 2022$1.72B-30.0%
Q3 FY2022Sep 30, 2022$2.31B+3.3%
Q2 FY2022Jun 30, 2022$2.03B+18.4%
Q1 FY2022Mar 31, 2022$1.74B-22.1%
Q4 FY2021Dec 31, 2021$2.45B-21.4%
Q3 FY2021Sep 30, 2021$2.24B+42.7%
Q2 FY2021Jun 30, 2021$1.72B+152.2%
Q1 FY2021Mar 31, 2021$2.24B+531.0%
Q4 FY2020Dec 31, 2020$3.12B+57.4%
Q3 FY2020Sep 30, 2020$1.57B+1.5%
Q2 FY2020Jun 30, 2020$680.00M+14.9%
Q1 FY2020Mar 31, 2020$355.00M-5.8%
Q4 FY2019Dec 31, 2019$1.98B+52.7%
Q3 FY2019Sep 30, 2019$1.55B-15.4%
Q2 FY2019Jun 30, 2019$592.00M-37.4%
Q1 FY2019Mar 31, 2019$377.00M-54.7%
Q4 FY2018Dec 31, 2018$1.30B+0.2%
Q3 FY2018Sep 30, 2018$1.83B+5.0%
Q2 FY2018Jun 30, 2018$946.00M-13.7%
Q1 FY2018Mar 31, 2018$833.00M+175.8%
Q4 FY2017Dec 31, 2017$1.30B+52.2%
Q3 FY2017Sep 30, 2017$1.74B+92.5%
Q2 FY2017Jun 30, 2017$1.10B–
Q1 FY2017Mar 31, 2017$302.00M–
Q4 FY2016Dec 31, 2016$851.00M–
Q3 FY2016Sep 30, 2016$905.00M–

More Abbott Laboratories figures

See a number that looks wrong?